newsfilter
← Latest News
Earnings Call Transcripts·

Vaxcyte Inc - 1781026 - VAXCYTE INC

  • Explicit Guidance:

    • Clinical Data Timing: Anticipates Phase 1 data for the Elixir (epigenetic silencing) LDL-C program in the first half of next year.
    • Program Advancement Timeline:
      • LPA (Lipoprotein(a)) program: Expected to enter the clinic next year.
      • Triglyceride program: Expected to enter the clinic the year after the LPA program (i.e., two years post-announcement).
    • Capital Efficiency Goal: IPO proceeds are projected to fund all three programs through to Phase 1 initial proof-of-concept data.
    • Therapeutic Persistence Target: Aims to develop an ultra-long-acting PCSK9 silencer with durability lasting multiple years to decades (referencing non-human primate data showing 720-day effect without reactivation).
  • Business-Segment Outlook:

    • Primary Indication (Cardiovascular Metabolic Disease): Focus remains on ASCVD (Atherosclerotic Cardiovascular Disease) prevention via lipid lowering. The company aims to achieve >35% LDL-C reduction (current standard is ~15–23% adherence-adjusted) to surpass RNAi (Inclisiran) and create a "best-in-class" molecule.
    • Secondary Programs (LPA & Triglycerides):
      • LPA: Targeting high-risk populations for primary prevention rather than secondary intervention, aiming to reduce LPA levels by >95%.
      • Triglycerides: Targeting severe hypertriglyceridemia (FCS/MCS categories) with >95% reduction in ApoC3 and triglycerides, aiming to transition patients from monthly RNAi/ASO therapies (e.g., Arrowhead, Ionis) to a curative, one-time treatment.
    • Platform Expansion: While primarily focused on cardiovascular/metabolic diseases, the platform (CasX/X-Editor and Elixir) allows for expansion into other therapeutic areas via partnering.
  • Market and Competitive Outlook:

    • Adherence Gap: Identifies a critical market failure in current lipid drugs where 70% of patients on small molecules and 50% on antibodies discontinue therapy within one year, compared to 20% non-re-dosing for RNAi. The company positions its durable therapy to solve this adherence bottleneck.
    • Target Population Shift: Unlike genome editing peers restricted to rare genetic subsets, the company expects to treat a broad population (adults with elevated LDL-C and risk), leveraging the safety profile of epigenetic silencing.
    • Pricing & Market Access: Anticipates a "competitive pricing" discussion potential due to COGS and the opportunity to treat the remaining 99% of patients not currently on PCSK9 inhibitors, potentially generating value for the healthcare system.
    • Competitive Landscape: Targets the transition of patients from existing RNAi/ASO competitors (Arrowhead, Ionis) to a potentially curative approach in the next 5+ years for triglycerides.
  • Macro / Industry Outlook:

    • Disease Burden: Cites new AHA/ESC statistics indicating 50% of males aged 30–50 have arterial plaque, framing ASCVD as the leading cause of global morbidity/mortality.
    • Preventative Paradigm: Shifts industry focus from late symptomatic intervention to early preventative genetic medicine, arguing that late-stage treatment (e.g., Horizon studies for LPA) yields limited clinical benefit compared to early intervention.
    • Regulatory Environment: Notes success in obtaining regulator approval to expand trial eligibility beyond rare genetic subsets to general elevated-risk populations.
  • Strategic Initiatives:

    • Technology Platform Evolution:
      • X-Editor: Evolution of CasX molecule through >120 steps in sequence space to achieve high potency/specificity with no off-target editing observed even at 10x supersaturation doses.
      • Elixir (Epigenetic Silencing): Application of non-DNA-damaging silencing to target PCSK9, LPA, and ApoC3.
    • Partnerships:
      • Sanofi: Expanded collaboration (4+ years) to utilize epigenetic silencing for in vivo sickle cell and undisclosed genetic medicines.
      • Lilly: Partnership for neurological and neuromuscular diseases.
      • Capitalization: Both Sanofi and Lilly invested in the recent IPO.
    • Grant Funding: Secured funding from the California Institute for Genetic Medicine to support the LPA and Triglyceride programs, significantly offsetting burn rate.
  • Risks and Headwinds to Outlook:

    • Clinical Development Risk: Future data points (next year for LPA, the year after for Triglycerides) are required to validate efficacy and safety; the company must select one program to advance immediately after the initial clinical trial results.
    • Off-Target Safety: Despite engineering claims of zero off-target effects in preclinical models (NHP, mice, hepatocytes), the risk of off-target editing remains a primary concern inherent to genome editing, requiring high regulatory scrutiny.
    • Toxicity: Monitor for lipid nanoparticle (LNP) related toxicity (ALT/AST/bilirubin), though preclinical data suggests indistinguishability from saline below 1 mg/kg doses.
    • Adoption/Commercial Execution: Success depends on overcoming the historical adherence issues of current lipid drugs; if patients do not accept a long-term intervention, the value proposition diminishes.
  • Management Tone on the Future:

    • Confidence Level: High confidence in the technology's ability to achieve decades-long persistence and zero off-target editing based on extensive non-human primate data.
    • Strategic Clarity: Emphasis on being a "highly disciplined, very focused" organization with lower capital burn than peers.
    • Hedges: Notes that human potency data from transgenic mice (2x potency) and primary hepatocytes (5–8x potency) should be viewed "with a grain of salt" as in vitro/in vivo translation varies.
    • Vision: Strong personal conviction that the therapy will "extend health span" and potentially "extend lifespan," positioning the company to capture the "protective genetics" market.
  • Miscellaneous:

    • Dosage Efficiency: Non-human primate data indicates full saturation and maximal LDL-C lowering at 0.75 mg/kg (therapeutic dose) with no epigenetic reactivation after 720 days.
    • Redosing Capability: Demonstrated ability to redose as close as 42 days apart without loss of tolerability or efficacy, allowing for titration if needed.
    • Humanization: Transgenic mouse and human hepatocyte models show potency increases of 2x to 8x compared to NHP data.
Company
VAXCYTE INC
Keywords
VAXCYTE INC